Autolus Therapeutics (AUTL) News Today

Autolus Therapeutics PLC (NASDAQ:AUTL) shares have risen today following better‐than‐expected quarterly results and encouraging clinical and commercial updates.

• Positive Sentiment: Q2 2025 results beat expectations, with EPS of ($0.18) vs. consensus ($0.24) and revenue of $13.5 million vs. $12.92 million forecast. MarketBeat EPS Beat
• Positive Sentiment: Company reported AUCATZYL® net product revenue of $20.9 million in Q2 and $29.9 million YTD, received conditional UK and EU marketing authorizations, presented long-term obe-cel remission data, and plans Phase 2 lupus nephritis and Phase 1 MS trials by year-end. GlobeNewswire Q2 Results & Updates
• Positive Sentiment: Analyst on Seeking Alpha remains bullish on obe-cel’s durable benefits and expanding indications, highlighting EU approval and potential in non-Hodgkin lymphoma and autoimmune diseases. Seeking Alpha Bullish Thesis
• Neutral Sentiment: Shares saw unusually high trading volume, prompting questions about whether this signals a buying opportunity. MarketBeat Volume Alert
• Neutral Sentiment: Q2 earnings call materials—including the transcript and presentation—are now available for investors to review detailed management commentary and guidance. Earnings Call Transcript
• Negative Sentiment: Wells Fargo cut its price target on AUTL from $6.00 to $5.00 despite an “overweight” rating, signaling some analyst caution on valuation. Benzinga Price Target Cut